YM BioSciences Inc. said Monday it has received Health Canada clearance for a Phase II trial of nimotuzumab in colorectal cancer patients who have not responded to previous treatments. The monoclonal antibody is to be tested on about 100 patients in Canada who will be treated with irinotecan plus nimotuzumab.